April 15, 2012 (Vol. 32, No. 8)

Tom Lyon has been appointed vp and site head at Hoffmann-La Roche in Nutley, NJ. Prior to this appointment, Lyon served as vp, site services for Genentech. He has also held positions at Bristol-Myers Squibb, including vp, global engineering.

Tom Lyon

CytomX Therapeutics appointed Hoyoung Huh, M.D., Ph.D., as chairman of its board of directors…Sangart promoted Frank Booth to CMO and appointed both Mary Rose Keller as vp, clinical operations and Carmen Betancourt-Riche as vp, regulatory affairs and quality assurance…Sirona Biochem appointed Pierre Vogel, Ph.D.Bernard Langlois, Ph.D., and Eric Leclerc, Ph.D., to the scientific advisory board of Sirona’s subsidiary, TChem…Cubist Pharmaceuticals added Alison Lawton to its board of directors…bluebird bio appointed David M. Davidson, M.D., as CMO…Scott M. Whitcup, M.D., joined Questcor Pharmaceuticals’ board of directors…Codexis appointed Peter Strumph as interim CEO.

Christopher Gallen, M.D., Ph.D., joined SK Biopharmaceuticals as CEO. He is also now CEO of the company’s American affiliate, SK Life Science. Before joining SK, Dr. Gallen was evp of Zalicus. Prior to that, he was president, CEO, and a member of the board of directors at Neuromed.

Christopher Gallen, M.D., Ph.D.

ChromaDex named Debra A. Heim COO and president of its consumer products division…Aptiv Solutions promoted Corey Dunham to svp, global data management and Angela Weston to svp, business development Europe; Aptiv also appointed Martin Geueke, Ph.D., svp, software development and Christopher Ellis vp, project management Europe…Viamet Pharmaceuticals appointed Richard Katz, M.D., as CBFO…Amarillo Biosciences appointed Stephen T. Chen, Ph.D., as chairman of the board and CEO…Preclinical Oncology Services hired Martin Page, Ph.D., as scientific consultant.

Synta Pharmaceuticals appointed Dvorit Samid, Ph.D., vp, medical affairs. Dr. Samid was previously vp, medical affairs at Allos Therapeutics. She has also held medical affairs-related positions at ImClone Systems, Abraxis Oncology, and Roche.

Dvorit Samid, Ph.D.

Biomatters appointed Karin Fredrikson as vp, U.S. operations and promoted Brett Ammundsen, Ph.D., to CEO…Fluxion Biosciences appointed Tom Driscoll as vp, marketing; Ali Yehia, Ph.D., as director, global IonFlux sales; Andrew Baxter, Ph.D., as European technical manager, IonFlux; and John Battista as BioFlux global sales and service director…Andrew Gengos joined PBS Biotech’s advisory board…Burt Adelman, M.D., joined Dyax as CMO…Dendreon appointed Joe DePinto as evp, global commercial operations; Robert S. Poulton as evp, technical operations; and Christine Mikail as evp, corporate development, general counsel, and secretary.

Thermo Fisher Scientific elected C. Martin Harris, M.D., to its board of directors, as well as the board’s nominating and governance committee. Dr. Harris is CIO and chairman of the information technology division of Cleveland Clinic in Ohio.

C. Martin Harris, M.D.

Leena Bruckner-Tuderman, M.D., Ph.D., Barbara Gilchrest, M.D., Anne Lucky, M.D., M. Peter Marinkovich, M.D., John McGrath, M.D., Karen Wiss, M.D., and David Woodley, M.D., are all now members of Lotus Tissue Repair’s clinical advisory board…Natural Molecular Testing named Karthikeshwar Kasirajan, M.D., CMO…Dynasil elected John Millerick to its board of directors…Cofactor Genomics hired Don Henricksen as North American sales director.

Seattle Genetics promoted Chris Boerner, Ph.D., to the position of svp, commercial. Dr. Boerner joined Seattle Genetics in November 2010 as vp, marketing. Prior to that, Dr. Boerner worked at Genentech for over eight years in various commerical roles, including director of marketing on Avastin.

Chris Boerner, Ph.D.

Simulations Plus elected David Ralph, Ph.D., to its board of directors and promoted John DiBella to vp, marketing and sales…Idenix Pharmaceuticals appointed Michael S. Wyzga to its board of directors and elected Thomas R. Hodgson as chairman of the board…ProMetic Life Sciences appointed John Moran, M.D., to its board of directors…Metabolix added Matthew Strobeck, Ph.D., to its board of directors.

Previous articleEngineered HSCs Differentiate into HIV-Specific CTLs that Hold Back HIV Infection In Vivo
Next articleNMR Structural Biology Firm Signs First Drug Discovery Collaboration with AstraZeneca